0.00
—
Close of 30 Oct 2026, in USD
About IR-Med
Its shares trade under the ticker IRME. It has been listed since 18 July 2001.
IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company is headquartered in New York City, New York. The company went IPO on 2001-07-18. The firm develops non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company’s devices allow healthcare professionals to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. Its initial product candidates are in various stages of development. The company is focused on two principal medical devices: PressureSafe and Nobiotics. PressureSafe is a handheld optical monitoring device that is being developed to support the early detection of pressure injuries (PI) to the skin and underlying tissue, primarily caused by prolonged pressure associated with bed confinement. Nobiotics is an otoscope, which is designed to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media) is of a bacterial origin.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 18 Jul 2001
- Employees
- 7
- Head office
- C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE, NEW YORK, NY, 10151
- Incorporated in
- NV
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Oded BashanExecutive Chairman of the Board, since 2020$273,728
- Mr. Ran ZiskindChief Executive Officer$69,767
- Mr. Sharon LevkovizChief Financial Officer
- Mr. Aharon KleinChief Technology Officer, Director, since 2024$122,324
- Mr. Ohad BashanDirector$14,351
- Mr. Yaniv CohenDirector
- Mr. Yechiel EvenIndependent Director
- Mr. Ron MayronIndependent Director$25,430
- Ms. Kathy CusumanoPresident, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IR-Med Inc's PressureSafe device detects pressure injuries in real-time without invasive procedures.
- Nobiotics otoscope provides immediate indications for medical diagnosis in healthcare settings.
- The company's focus on IR and AI technologies enables non-invasive medical device development.
Weaknesses
- IR-Med Inc has only 7 full-time employees, limiting operational capacity.
- The company's initial product candidates are in various stages of development.
- IR-Med Inc's IPO in 2001 has not led to significant market expansion.
Opportunities
- The US healthcare market offers growth potential for non-invasive medical devices.
- IR-Med Inc can expand its product line in the Health Care sector.
- New developments in AI and IR technologies present opportunities for innovation.
Threats
- Competition in the Health Care sector may impact IR-Med Inc's market position.
- Regulatory challenges in medical device development could delay product launches.
- The limited employee count may hinder response to market demands.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.